Carlos M's Avatar

Carlos M

@carlosmmed.bsky.social

Medicina Interna. Autoinmunes. Madrid. España.

10 Followers  |  12 Following  |  1 Posts  |  Joined: 23.11.2024  |  1.4288

Latest posts by carlosmmed.bsky.social on Bluesky

Preview
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis | NEJM Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving stan...

Obinituzumab in NL in NEJM 2025.
But… complete renal response 30.9% in the placebo group?

www.nejm.org/doi/full/10....

08.02.2025 18:31 — 👍 1    🔁 0    💬 0    📌 0

@carlosmmed is following 12 prominent accounts